Identification of a cyanogen bromide fragment of porcine type II collagen capable of modulating collagen arthritis in B10.RIII (H-2r) mice.
Previous studies directed towards identifying epitopes on type II collagen (CII) important in collagen induced arthritis (CIA) in mice have focused primarily on responses mounted in susceptible H-2q strains. However, the nature of T and B cell responses against CII in susceptible H-2r strains remains ill-defined. In an effort to identify regions on CII important in CIA in H-2r mice, we examined the cellular and humoral response of susceptible B10.RIII (H-2r) mice against cyanogen bromide (CB)-cleaved fragments of porcine CII. Following immunization with native porcine CII, LNC from B10.RIII mice mounted proliferative responses predominantly to peptide CB10, while negligible proliferation was detected against fragment CB9, 7, CB8, CB11 or CB12. In contrast, sera from arthritic B10.RIII mice displayed a heterogeneous pattern of reactivity against porcine CII, with strong antibody binding measured against the major fragments CB11, CB8 and CB10. To determine the in vivo significance of the dominant cellular response to CB10, B10.RIII mice received an i.v. injection of soluble CB10 seven days before immunization with native porcine CII. Mice pretreated with CB10 were highly resistant to CIA compared to control animals. Interestingly, B10.RIII mice pretreated with fragment CB11, a region of CII implicated in H-2q restricted CIA, remained susceptible to arthritis induction. Collectively, our findings indicate that the CB10 region of porcine C11 bears determinants which may be important in the induction and/or regulation of CIA in the H-2r haplotype.
Nabozny
G H
GH
Department of Immunology, Mayo Graduate School of Medicine, Rochester, MN 55905, USA.
Griffiths
M M
MM
Harper
D S
DS
Luthra
H S
HS
David
C S
CS
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D001168:Arthritis / Q000209:etiology* / Q000276:immunology / Q000628:therapy; D003094:Collagen / Q000276:immunology*; D003433:Crosses, Genetic; D003488:Cyanogen Bromide; D005260:Female; D007113:Immunity, Innate; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000145:classification; D007275:Injections, Intravenous; D008198:Lymph Nodes / Q000166:cytology; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010446:Peptide Fragments / Q000276:immunology* / Q000302:isolation & purification / Q000627:therapeutic use; D013552:Swine; D013601:T-Lymphocytes / Q000276:immunology
D000276:Adjuvants, Immunologic; D007074:Immunoglobulin G; D010446:Peptide Fragments; D003094:Collagen; D003488:Cyanogen Bromide